TY - JOUR
T1 - USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation
AU - Palazón-Riquelme, Pablo
AU - Worboys, Jonathan D
AU - Green, Jack
AU - Valera, Ana
AU - Martín-Sánchez, Fatima
AU - Pellegrini, Carolina
AU - Brough, David
AU - López-Castejón, Gloria
N1 - Funding Information:
This work was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 104192/Z/14/Z) to G.L-C, by the Manchester Collaborative Centre for Inflammation Research, a joint initiative of the University of Manchester, AstraZeneca, and GlaxoSmithKline and by a Medical Research Council (MRC) grant (MR/ N029992/1) to D.B. The Bioimaging Facility microscopes used in this study were purchased with grants from BBSRC, Wellcome Trust and the University of Manchester Strategic Fund. The authors thank Dr Gareth Howell (Manager, Manchester University Core Flow Cytometry Facility) for technical assistance with cell sorting.
Publisher Copyright:
© 2018 The Authors. Published under the terms of the CC BY 4.0 license
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/10
Y1 - 2018/10
N2 - The assembly and activation of the inflammasomes are tightly regulated by post-translational modifications, including ubiquitin. Deubiquitinases (DUBs) counteract the addition of ubiquitin and are essential regulators of immune signalling pathways, including those acting on the inflammasome. How DUBs control the assembly and activation of inflammasomes is unclear. Here, we show that the DUBs USP7 and USP47 regulate inflammasome activation in macrophages. Chemical inhibition of USP7 and USP47 blocks inflammasome formation, independently of transcription, by preventing ASC oligomerisation and speck formation. We also provide evidence that the ubiquitination status of NLRP3 itself is altered by inhibition of USP7 and USP47. Interestingly, we found that the activity of USP7 and USP47 increased in response to inflammasome activators. Using CRISPR/Cas9 in the macrophage cell line THP-1, we show that inflammasome activation is reduced when both USP7 and USP47 are knocked down. Altogether, these data reveal a new post-transcriptional role for USP47 and USP7 in inflammation by regulating inflammasome activation and the release of the pro-inflammatory cytokines IL-1β and IL-18, and implicate dual USP7 and USP47 inhibitors as potential therapeutic agents for inflammatory disease.
AB - The assembly and activation of the inflammasomes are tightly regulated by post-translational modifications, including ubiquitin. Deubiquitinases (DUBs) counteract the addition of ubiquitin and are essential regulators of immune signalling pathways, including those acting on the inflammasome. How DUBs control the assembly and activation of inflammasomes is unclear. Here, we show that the DUBs USP7 and USP47 regulate inflammasome activation in macrophages. Chemical inhibition of USP7 and USP47 blocks inflammasome formation, independently of transcription, by preventing ASC oligomerisation and speck formation. We also provide evidence that the ubiquitination status of NLRP3 itself is altered by inhibition of USP7 and USP47. Interestingly, we found that the activity of USP7 and USP47 increased in response to inflammasome activators. Using CRISPR/Cas9 in the macrophage cell line THP-1, we show that inflammasome activation is reduced when both USP7 and USP47 are knocked down. Altogether, these data reveal a new post-transcriptional role for USP47 and USP7 in inflammation by regulating inflammasome activation and the release of the pro-inflammatory cytokines IL-1β and IL-18, and implicate dual USP7 and USP47 inhibitors as potential therapeutic agents for inflammatory disease.
KW - inflammasome
KW - deubiquitination
KW - USP7
KW - USP47
KW - macrophages
KW - interleukin-1
U2 - 10.15252/embr.201744766
DO - 10.15252/embr.201744766
M3 - Article
C2 - 30206189
SN - 1469-3178
VL - 19
JO - EMBO reports
JF - EMBO reports
IS - 10
M1 - e44766
ER -